Furthermore, accurate delineation of tumor extent to ensure a maximal resection is also of particular interest in patients with IDH-mutant gliomas, as even minimal tumor remnants after surgery may negatively impact overall survival [55]. The gene discussed is IDH2; the disease is central nervous system cancer.